Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW 2145, Australia.
Breast. 2012 Dec;21(6):724-9. doi: 10.1016/j.breast.2012.09.001. Epub 2012 Oct 23.
The aim of this study was to determine the impact of universal HER2 testing on the clinico-pathologic profile of HER2+ breast cancer. Data were extracted from breast cancer pathology reports spanning two periods: before (2003/4, n = 379), and after (2008/9, n = 560) the introduction of universal testing. In 2003/4, 43.3% of breast cancers were tested for HER2 with 16% of tested cases HER2+. In 2008/9, 98.4% of cases were tested with 14.7% HER2+. In 2008/9, HER2+ status was associated with younger age, higher grade, increased tumour size, lymph node involvement, negative oestrogen and/or progesterone receptor status. HER2+ cases diagnosed in 2003/4 were not significantly different in respect of these features. The rate of HER2+ breast cancer amongst screen detected cases in 2008/9 was 8.3%. The phenotype of HER2+ breast cancer was stable following the introduction of universal testing. The overall rate of HER2+ breast cancer was influenced by screen detection.
本研究旨在确定普遍进行 HER2 检测对 HER2+乳腺癌临床病理特征的影响。从两个时期的乳腺癌病理报告中提取数据：引入普遍检测之前（2003/4，n=379）和之后（2008/9，n=560）。在 2003/4 年，43.3%的乳腺癌进行了 HER2 检测，其中 16%的检测病例 HER2+。在 2008/9 年，98.4%的病例进行了检测，其中 14.7% HER2+。在 2008/9 年，HER2+状态与年龄较小、分级较高、肿瘤大小增加、淋巴结受累、雌激素和/或孕激素受体状态阴性有关。在 2003/4 年诊断的 HER2+病例在这些特征方面没有显著差异。2008/9 年筛查检测到的 HER2+乳腺癌病例的发生率为 8.3%。在普遍检测引入后，HER2+乳腺癌的表型保持稳定。HER2+乳腺癌的总体发生率受筛查检测的影响。
